Skip to main content
Premium Trial:

Request an Annual Quote

Illumina, Blue Cross Blue Shield Association Partner on Precision Medicine Report

NEW YORK (GenomeWeb) – Illumina and the Blue Cross Blue Shield Association will partner in order to develop a better understanding of the state of precision medicine in the US.

The companies said they plan to write a report on the utilization of precision medicine by early 2019 that details the availability and clinical understanding of DNA sequencing technologies, genetic testing, and precision medicine. In addition, the companies also plan to provide educational programs to healthcare providers in areas that they identify as currently having limited access.

"Through our partnership with Illumina, we'll have a better understanding of how precision medicine is being used so we can avoid inequities by ensuring all Americans have access to these lifesaving treatments that are tailored to their individual health needs," Trent Haywood, senior vice president and chief medical officer for the Blue Cross Blue Shield Association, said in a statement.

Phillip Febbo, Illumina's chief medical officer and senior vice president, also noted that "health care providers need to be educated on both the clinical accuracy and usefulness of next generation sequencing."

The Scan

Could Mix It Up

The US Food and Drug Administration is considering a plan that would allow for the mixing-and-matching of SARS-CoV-2 vaccines and boosters, the New York Times says.

Closest to the Dog

New Scientist reports that extinct Japanese wolf appears to be the closest known wild relative of dogs.

Offer to Come Back

The Knoxville News Sentinel reports that the University of Tennessee is offering Anming Hu, a professor who was acquitted of charges that he hid ties to China, his position back.

PNAS Papers on Myeloid Differentiation MicroRNAs, Urinary Exosomes, Maize Domestication

In PNAS this week: role of microRNAs in myeloid differentiation, exosomes in urine, and more.